Cisplatin for pancreatic cancer with HRD
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug cisplatin in patients with advanced pancreatic cancer that has a specific DNA repair problem called homologous recombination deficiency (HRD). It may offer a new treatment option for those whose cancer has progressed after at least one prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with advanced pancreatic cancer that has grown after at least one previous chemotherapy.
- You have a type of DNA repair problem called homologous recombination deficiency (HRD), confirmed by a genetic test.
- You have a tumor that can be measured on a scan (at least one measurable lesion).
- Your doctor says you are well enough to receive the treatment, with good kidney and other organ function.
- You have not received a platinum chemotherapy drug or a PARP inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.